eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

vol. 11
Original paper

Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel space

Michael Chao, Darren Ow, Huong Ho, Yee Chan, Daryl Lim Joon, Sandra Spencer, Nathan Lawrentschuk, Mario Guerrieri, Trung Pham, Kevin McMillan, Alwin Tan, Farshad Foroudi, Johann Tang, Jason Wasiak, Madalena Liu, George Koufogiannis, Chee Wee Cham, Damien Bolton

J Contemp Brachytherapy 2019; 11, 1: 8–13
Online publish date: 2019/02/11
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
To report on rectal dosimetric and toxicity outcomes of intermediate and high-risk prostate cancer patients undergoing combined high-dose-rate (HDR) brachytherapy and external beam radiotherapy (EBRT) with or without hydrogel spacer (HS) insertion.

Material and methods
A total of 97 patients were analyzed in this study, with 32 patients (33%) who had HS insertion compared with a preceding group of 65 patients (67%) without HS. HS safety, the dosimetric effects on organs at risk (rectal, urethral, penile bulb, and bladder) as well as gastrointestinal (GI) and genitourinary toxicity were evaluated and compared between the two groups.

The median prostate-rectal separation achieved with HS was 10 mm (range, 5-14 mm). There were no post-operative complications following HS insertion. Patients with HS had significantly lower radiation dose to the rectum across all rectal dose volumes from rV30 to rV80, whether in absolute volume (cc) or as percentage of contoured OAR (p < 0.001). There was also significantly less acute > grade 1 GI toxicity (12.5% vs. 30.8%, p = 0.05) and a trend towards less late grade 1 GI toxicity (0% vs. 7.7%; p = 0.11) in the HS group compared to the non-HS group.

Insertion of HS in prostate cancer patients receiving combined HDR and EBRT is safe and has resulted in a significant radiation dose reduction to the rectum, resulting in significantly less acute GI toxicity and a trend towards less late GI toxicity.


prostate cancer, hydrogel spacer, high-dose-rate, brachytherapy, rectal protection

Hannoun-Lévi JM. Brachytherapy for prostate cancer: Present and future. Cancer Radiother 2017; 21: 469-472.
Stish BJ, Davis BJ, Mynderse LA et al. Brachytherapy in the management of prostate cancer. Surg Oncol Clin N Am 2017; 26: 491-513.
Skowronek J. Current status of brachytherapy in cancer treatment – short overview. J Contemp Brachytherapy 2017; 9: 581-589.
Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options. J Contemp Brachytherapy 2013; 5: 33-41.
Morton GC. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachytherapy 2014; 6: 323-330.
Kee DLC, Gal J, Falk AT et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Cancer Treat Rev 2018; 70: 265-271.
Mariados N, Sylvester J, Shah D et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2015; 92: 971-977.
Pinkawa M, Berneking V, Schlenter M et al. Quality of life after radiation therapy for prostate cancer with a hydrogel spacer: 5-year results. Int J Radiat Oncol Biol Phys 2017; 99: 374-377.
Chao M, Ho H, Chan Y et al. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. BJU Int 2018; 122: 427-433.
Pinkawa M, Corral NE, Caffaro M et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2011; 100: 436-441.
Hsu IC, Bae K, Shinohara K et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010; 78: 751-758.
Strom TJ, Wilder RB, Fernandez DC et al. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy +/-intensity modulated radiation therapy. Radiother Oncol 2014; 111: 126-131.
Yeh J, Lehrich B, Tran C et al. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 2016; 15: 283-287.
Wu SY, Boreta L, Wu A et al. Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy. Brachytherapy 2018; 17: 259-264.
Hepp R, Eggert T, Schabl G et al. Salvage high-dose-rate brachytherapy for prostate cancer persistence after brachytherapy: repeated use of a polyethylene glycol hydrogel spacer. J Contemp Brachytherapy 2018; 10: 169-173.
Hamstra DA, Mariados N, Sylvester J et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase iii trial. Int J Radiat Oncol Biol Phys 2017; 97: 976-985.
Prada PJ, Fernandez J, Martinez AA et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007; 69: 95-102.
Sathya JR, Davis IR, Julian JA et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199.
Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
Spratt DE, Zumsteg ZS, Ghadjar P et al. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 2014; 114: 360-367.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe